Wrap Matrix products

Levetiracetam, an anti-epileptic with high solubility and very large dose has been developed as a 1000 mg and 1500 mg tablet and bioequivalent to Keppra. Pivotal pharmacokinetic studies have been completed, and we intend to file this product as a 505 b(2) filing.

A skeletal muscle relaxant with an ultra short half life that has been designed to offer better therapeutic action over the repeat dose IR product currently available, is in Phase I studies.

A controlled release formulation has been developed for a cardiovascular agent with high dose and high solubility. The product is in pharmacokinetic studies. Combinations with various drugs with complementary mechanisms of action are under development

An anticancer combination, two CNS agents are also being worked on.

Eight controlled release products based on this technology have already been launched in India . They include molecules like Metoprolol (antihypertensive ) & its combinations , Ropinirole , Pramipexole & Bupropion.

Venlafaxine ER (antidepressant), based on this technology, has already been approved by EU & US FDA. Two more ANDAs have been filed with the USFDA.

Products with a very high dose can be formulated into a simple-to-swallow tablet using this technology. Since the release profile with this technology is not simple to copy, the risk of generics is limited.